WFSBP Programme 2015

30 / 112

28
Scientific Programme | Monday, 15 June 2015
WFSBP 2015
T6: Bipolar Disorders: Basic/ Clinical
TG-01 WFSBP Treatment Guidelines
11:00–12:30 MC 3 Room
Task Force on Bipolar Disorders: Improving longitudinal
treatment for bipolar disorders including mixed states
guidelines
Chair: Siegfried Kasper, Austria
Co-Chair: Heinz Grunze, United Kingdom
TG-01-001
Bipolar mixed state guideline development
Heinz Grunze, United Kingdom
TG-01-002
Long term illness trajectories and their management
Eduard Vieta, Spain
TG-01-003
Multistate outcome and persistent benefit analysis
Charles L. Bowden, USA
T16: Genetics
TG-02 WFSBP Treatment Guidelines
15:00–16:30 Skalkotas Hall
Task Force on Genetics
Chair: Dan Rujescu, Germany
Co-Chair: Mick C. O‘Donovan, United Kingdom
TG-02-001
Genomics of schizophrenia: Results from the largest as-
sociation study so far
Mick C. O‘Donovan, United Kingdom
TG-02-002
The genetics of schizophrenia: Back to family studies
Lynn Delisi, USA
TG-02-003
Genetics of intermediate phenotypes: Focus on cognition
Dan Rujescu, Germany
TG-02-004
Clinical application of psychiatric pharmacogenetic testing
James Kennedy, Canada
T32: Pharmacology
RT-01 Round Table
11:00–12:30 Trianti Hall
Drug discovery in neuroscience: Why is big pharma re-
luctant to continue investing?
Chair: Lakshmi Yatham, Canada
Co-Chair: Shigenobu Kanba, Japan
Discussants:Carlos A. Zarate, USA
Michel Bourin, France
Raimund Buller, Denmark
Maeda Kenji, Japan
Sanjeev Pathak, USA
Matcheri S. Keshavan, USA
T6: Bipolar Disorders: Basic/ Clinical
WS-01 Workshop
16:30–18:00 Skalkotas Hall
Lithium phobia: Science or superstition?
Chair: Digvijay Goel, New Zealand
Co-Chair: Mohan Isaac, Australia
WS-01-001
Lithium: Science or superstition?
Digvijay Goel, New Zealand
WS-01-002
Lithium: The magic ion
Shailesh Kumar, New Zealand
WS-01-003
Lithium vs. sodium valproate: Understanding the dilemma
Rajesh Nagpal, India
WS-01-004
Lithium: The way forwards
Mohan Isaac, Australia